We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+7.83%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.71B
AUM Growth
-$70.8M
(-4%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-1.56%
Top 10 Holdings %
Top 10 Hldgs %
65.15%
Holding
70
New
6
Increased
13
Reduced
5
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$30.3M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$24.8M |
| 3 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$23.4M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
+$22.7M |
| 5 |
MRNS
Marinus Pharmaceuticals, Inc
MRNS
|
+$21.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Protagonist Therapeutics
PTGX
|
+$41.4M |
| 2 |
Design Therapeutics
DSGN
|
+$32.4M |
| 3 |
ETNB
89bio
ETNB
|
+$25.6M |
| 4 |
Axsome Therapeutics
AXSM
|
+$24.4M |
| 5 |
Viridian Therapeutics
VRDN
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.77% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$1.56B
| $464M | 27.07% |
8,142,100
| – | – |
|
2
BridgeBio Pharma
BBIO
$16.4B
| $123M | 7.17% |
4,662,530
+493,351
| +12% | +$14M |
|
|
AMAM
3
DELISTED
Ambrx Biopharma Inc
AMAM
| $114M | 6.66% |
9,923,689
+307,534
| +3% | +$4.19M |
|
|
ACLX
4
DELISTED
Arcellx
ACLX
| $77.1M | 4.5% |
2,150,000
+150,000
| +8% | +$5.17M |
|
|
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
| $76.1M | 4.44% |
2,000,000
+690,000
| +53% | +$30.3M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $57.4M | 3.35% |
3,850,000
+50,000
| +1% | +$663K |
|
7
Olema Pharmaceuticals
OLMA
$977M
| $55.6M | 3.25% |
4,504,764
+1,422,764
| +46% | +$14.5M |
|
8
Structure Therapeutics
GPCR
$3.37B
| $53.3M | 3.11% |
1,056,373
+480,000
| +83% | +$15.5M |
|
9
Biomea Fusion
BMEA
$88.2M
| $49.1M | 2.87% |
3,570,872
| – | – |
|
10
Immunovant
IMVT
$7.93B
| $47M | 2.74% |
1,225,000
+675,000
| +123% | +$15.3M |
|
11
Tarsus Pharmaceuticals
TARS
$2.55B
| $46.6M | 2.72% |
2,621,422
+1,200,000
| +84% | +$21.2M |
|
12
Cabaletta Bio
CABA
$427M
| $43.8M | 2.56% |
2,879,424
+657,685
| +30% | +$8.99M |
|
13
Vaxcyte
PCVX
$7.65B
| $33.9M | 1.98% |
665,000
| – | – |
|
|
14
Crinetics Pharmaceuticals
CRNX
$8.88B
| $32.8M | 1.91% |
+1,101,904
| New | +$22.7M |
|
15
Immuneering
IMRX
$262M
| $32.3M | 1.88% |
4,204,364
| – | – |
|
16
Pharvaris
PHVS
$2.28B
| $28.4M | 1.66% |
1,361,460
+387,846
| +40% | +$7.15M |
|
|
RYZB
17
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $26.2M | 1.53% |
+1,182,263
| New | +$24.8M |
|
18
EyePoint Inc
EYPT
$999M
| $25.6M | 1.49% |
3,200,000
| – | – |
|
|
KRTX
19
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $23.7M | 1.38% |
140,000
+60,000
| +75% | +$11.3M |
|
|
ALPN
20
DELISTED
Alpine Immune Sciences Inc
ALPN
| $21.8M | 1.27% |
+1,900,000
| New | +$23.4M |
|
21
Erasca
ERAS
$6.15B
| $21.3M | 1.24% |
10,813,246
| – | – |
|
|
JBIO
22
Jade Biosciences
JBIO
$1.18B
| $21.2M | 1.24% |
44,620
| – | – |
|
|
MRNS
23
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $21.1M | 1.23% |
+2,625,000
| New | +$21.8M |
|
24
Rhythm Pharmaceuticals
RYTM
$7.31B
| $19.5M | 1.14% |
850,000
+250,000
| +42% | +$5.6M |
|
25
Edgewise Therapeutics
EWTX
$4.28B
| $16.9M | 0.99% |
2,946,887
| – | – |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
CCA
LBC
C
Cormorant Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Cormorant Asset Management held 70 positions worth $1.71B, down 4% from $1.79B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Cormorant Asset Management's Q3 2023 filing shows 6 new, 13 increased, 5 reduced and 21 closed positions. Its largest new stake was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M. The largest sale was Protagonist Therapeutics, an estimated $41.4M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.
- Cormorant Asset Management's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,182,263 shares worth $26.2M.
- Cormorant Asset Management added most to Apellis Pharmaceuticals in Q3 2023, an estimated $30.3M increase.
- Cormorant Asset Management's biggest Q3 2023 reduction was Enliven Therapeutics, cutting an estimated $12.1M.
- Cormorant Asset Management fully exited Protagonist Therapeutics in Q3 2023, selling an estimated $41.4M.
- Cormorant Asset Management's ten largest holdings make up 65% of its $1.71B portfolio in Q3 2023.
- Cormorant Asset Management opened 6 new positions and closed 21 in Q3 2023.
- Cormorant Asset Management's portfolio value fell 4% quarter-over-quarter to $1.71B.
Based on Cormorant Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.